135 related articles for article (PubMed ID: 9241765)
1. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
Muntean W; Zenz W; Edlinger G; Beitzke A
Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
[No Abstract] [Full Text] [Related]
2. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
3. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child.
Muntean W; Zenz W; Finding K; Zobel G; Beitzke A
Acta Paediatr; 1994 Jan; 83(1):84-7. PubMed ID: 8193480
[TBL] [Abstract][Full Text] [Related]
5. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
Savage WJ; Kickler TS; Takemoto CM
Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
[TBL] [Abstract][Full Text] [Related]
6. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases.
Bomgaars L; Carberry K; Fraser C; West A; Teruya J
Congenit Heart Dis; 2010; 5(3):303-8. PubMed ID: 20576051
[TBL] [Abstract][Full Text] [Related]
7. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
Lo CY; Jones C; Glader B; Zehnder JL
Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
[TBL] [Abstract][Full Text] [Related]
8. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin.
Israels SJ; Leaker MT
J Pediatr; 1997 Sep; 131(3):480-3. PubMed ID: 9329435
[TBL] [Abstract][Full Text] [Related]
9. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant.
Zumberg MS; Waples JM; Kao KJ; Lottenberg R
Am J Hematol; 2000 May; 64(1):59-63. PubMed ID: 10815789
[TBL] [Abstract][Full Text] [Related]
10. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V.
Bänninger H; Hardegger T; Tobler A; Barth A; Schüpbach P; Reinhart W; Lämmle B; Furlan M
Br J Haematol; 1993 Nov; 85(3):528-32. PubMed ID: 8136275
[TBL] [Abstract][Full Text] [Related]
11. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.
Streiff MB; Ness PM
Transfusion; 2002 Jan; 42(1):18-26. PubMed ID: 11896308
[TBL] [Abstract][Full Text] [Related]
12. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
Cmolik BL; Spero JA; Magovern GJ; Clark RE
J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
[TBL] [Abstract][Full Text] [Related]
13. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
Crow SS; Sullivan VV; Aysola AE; Key NS; Harker-Murray P; Foker JE; Steiner ME
Ann Thorac Surg; 2007 Apr; 83(4):1547-9. PubMed ID: 17383385
[TBL] [Abstract][Full Text] [Related]
14. [A case positive for the inhibitor for coagulation factor V].
Nakagoshi R; Takamiya O; Nakata S; Ishikawa S; Higuchi Y; Okumura N; Ogiso Y
Rinsho Byori; 1999 Oct; 47(10):971-5. PubMed ID: 10590673
[TBL] [Abstract][Full Text] [Related]
15. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin.
Neschis DG; Heyman MR; Cheanvechai V; Benjamin ME; Flinn WR
J Vasc Surg; 2002 Feb; 35(2):400-2. PubMed ID: 11854743
[TBL] [Abstract][Full Text] [Related]
16. Fibrin sealant in the United States: clinical use at the University of Virginia.
Spotnitz WD
Thromb Haemost; 1995 Jul; 74(1):482-5. PubMed ID: 8578510
[TBL] [Abstract][Full Text] [Related]
17. Immunological consequences of topical bovine thrombin.
Zehnder JL; Leung LL
Am J Pathol; 2001 Dec; 159(6):2371. PubMed ID: 11733385
[No Abstract] [Full Text] [Related]
18. Acquired factor V inhibitor-related severe bleeding due to unformed prothrombinase complex.
Mitsuhashi T; Takamiya O
Thromb Res; 2018 Nov; 171():81-83. PubMed ID: 30267973
[No Abstract] [Full Text] [Related]
19. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin.
Tarantino MD; Ross MP; Daniels TM; Nichols WL
J Pediatr Hematol Oncol; 1997; 19(3):226-31. PubMed ID: 9201145
[TBL] [Abstract][Full Text] [Related]
20. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
Spero JA
J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]